340 studies found for:    VEGFR
Show Display Options
Rank Status Study
1 Terminated
Has Results
Human Leukocyte Antigen-A*02:01-restricted Tumor Vessel Specific Peptide Vaccination for Advanced Pancreatic Cancer
Conditions: Pancreatic Cancer;   Pancreas Neoplasms
Intervention: Biological: HLA-A*02:01-restricted VEGFR1-derived peptide vaccination
2 Unknown  Human Leukocyte Antigen-A*2402-Restricted Tumor Vessel Specific Peptide Vaccination for Advanced Pancreatic Cancer
Conditions: Pancreatic Cancer;   Pancreas Neoplasms
Intervention: Biological: VEGFR1-A24-1084 (SYGVLLWEI)
3 Unknown  HLA-A*0201 Restricted Peptide Vaccine Therapy With Gemcitabine With Gemcitabine in Patient Pancreatic Cancer (Phase1)
Condition: Pancreatic Cancer
Interventions: Biological: VEGFR1, VEGFR2;   Drug: Gemcitabine
4 Completed Anti-VEGFR Vaccine Therapy in Treating Patients With Neovascular Maculopathy
Conditions: Neovascular Maculopathy;   Age Related Macular Degeneration
Intervention: Biological: VEGFR1 and VEGFR2
5 Recruiting Treating Metastatic Cancer With Anti-VEGFR2 Gene Engineered CD8+ Lymphocytes
Conditions: Metastatic Cancer;   Metastatic Melanoma;   Renal Cancer;   Colorectal Cancer;   Ovarian Cancer;   Lung Cancer
Interventions: Genetic: Anti-VEGFR2 CAR CD8 plus PBL;   Drug: Cyclophosphamide;   Drug: Aldesleukin;   Drug: Fludarabine
6 Not yet recruiting VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Docetaxel in Treating Patients With Solid Tumors
Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: VEGFR/PDGFR dual kinase inhibitor X-82;   Drug: docetaxel;   Other: fluorine F 18 fluorothymidine;   Procedure: positron emission tomography/computed tomography;   Other: pharmacological study;   Other: laboratory biomarker analysis
7 Completed Antiangiogenic Peptide Vaccine Therapy With Gemcitabine in Treating Patient With Pancreatic Cancer (Phase1/2)
Condition: Pancreatic Cancer
Interventions: Biological: VEGFR1-1084, VEGFR2-169;   Drug: Gemcitabine
8 Active, not recruiting Antiangiogenic Peptide Vaccine Therapy With Gemcitabine in Treating Patient With Pancreatic Cancer
Condition: Pancreatic Cancer
Intervention: Biological: VEGFR1-1084, VEGFR2-169, and gemcitabine
9 Unknown  Antiangiogenic Peptide Vaccine Therapy in Treating Patient With Hepatocellular Carcinoma
Condition: Hepatocellular Carcinoma
Intervention: Biological: antiangiogenic paptide vaccine
10 Completed Gemcitabine With Antiangiogenic Peptide Vaccine Therapy in Patients With Pancreatic Cancer
Condition: Pancreatic Cancer
Intervention: Biological: VEGFR2-169 and gemcitabine
11 Terminated Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Breast Cancer
Condition: Breast Cancer
Intervention: Biological: VEGFR1 and VEGFR2
12 Terminated Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Colorectal Cancer
Conditions: Colorectal Cancer;   Colon Cancer;   Rectal Cancer
Intervention: Biological: VEGFR1 and VEGFR2
13 Completed Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Esophageal Cancer
Condition: Esophageal Cancer
Intervention: Biological: URLC10, VEGFR1 and VEGFR2
14 Unknown  Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Non-Small Cell Lung Cancer
Condition: Non Small Cell Lung Cancer
Intervention: Biological: URLC10, VEGFR1 and VEGFR2
15 Completed Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Gastric Cancer
Condition: Gastric Cancer
Intervention: Biological: URLC10, VEGFR1 and VEGFR2
16 Completed Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Gastric Cancer
Condition: Gastric Cancer
Intervention: Biological: URLC10, KOC1, VEGFR1 and VEGFR2
17 Terminated Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Colorectal Cancer
Conditions: Colorectal Cancer;   Colon Cancer;   Rectal Cancer
Intervention: Biological: RNF43, TOMM34, VEGFR1 and VEGFR2
18 Recruiting Study of Oral Lucitanib (E-3810), a Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, in Patients With Solid Tumors
Condition: Solid Tumors
Intervention: Drug: Lucitanib
19 Active, not recruiting MET/VEGFR2 Inhibitor GSK1363089 and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer That Has Not Responded to Previous Chemotherapy
Condition: Lung Cancer
Interventions: Drug: MET/VEGFR2 inhibitor Foretinib;   Drug: erlotinib hydrochloride;   Other: laboratory biomarker analysis
20 Completed A Study of RO4929097 in Patients With Advanced Renal Cell Carcinoma That Have Failed Vascular Endothelial Growth Factor (VEGF)/Vascular Endothelial Growth Factor Receptor (VEGFR) Therapy
Conditions: Clear Cell Renal Cell Carcinoma;   Recurrent Renal Cell Cancer;   Stage IV Renal Cell Cancer
Interventions: Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097;   Other: laboratory biomarker analysis

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years